Tag: Alteogen

Alteogen's Terghaz was awarded Best Biotechnology Product at the 2026 Prigalien Korea Awards for its recombinant human hyaluronidase.

Alteogen has signed an option and licensing agreement with Novartis to develop and commercialize subcutaneous formulations based on its ALT-B4 technology, with potential payments of up to $3.22 billion plus royalties.

Alteogen has signed an exclusive licensing agreement with a global pharmaceutical company for the development of subcutaneous biopharmaceuticals.

Alteogen is nearing global licensing deals, focusing on maximizing value and expanding its platform technology in biopharma.

Alteogen partners with Biogen for exclusive licensing of subcutaneous biopharmaceuticals, potentially earning up to 549 million USD.

Alteogen secures a U.S. patent for a subcutaneous Keytruda formulation using ALT-B4, ensuring exclusivity until 2043 and potential $1B in sales.